Table 1.
Characteristics of included study participants
| Disease status | HC | MS |
|---|---|---|
| No. samples | 317 | 637 |
| No. of participants | 241 | 515 |
| Age, y, mean (SD) | 35.85 (15.71) | 42.54 (14.91) |
| Age range (min, max) | 7, 84 | 7, 76 |
| Female gender, n (%) | 224 (70.66) | 468 (73.47) |
| White race, n (%) | 253 (79.81) | 542 (85.09) |
| Disease duration, y, mean (SD) | – | 13.45 (10.63) |
| Progressive MS, n (%) | – | 205 (32.18) |
| EDSS (417 scores available), median (IQR) | – | 2.50 (1.50, 5.00) |
| Use of cane, n (%) | – | 97 (23.2) |
| Disease-modifying therapy, n (%) | – | – |
| No treatment | – | 195 (30.61) |
| Interferon-β | – | 60 (9.42) |
| Glatiramer acetate | – | 130 (20.41) |
| Dimethyl fumarate | – | 36 (5.65) |
| Teriflunomide | – | 2 (0.31) |
| Natalizumab | – | 82 (12.87) |
| Alemtuzumab | – | 2 (0.31) |
| Daclizumab | – | 1 (0.16) |
| Mycophenolate mofetil | – | 2 (0.31) |
| Ocrelizumab | – | 1 (0.16) |
| Rituximab | – | 14 (2.2) |
| Missing | – | 112 (17.58) |